Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 2/20 | 0.54 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.54 |
| ▸ | AURKA | O14965 | 1/20 | 0.54 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.54 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.54 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.54 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.54 |
| ▸ | CSF1R | P07333 | 1/20 | 0.54 |
| ▸ | RET | P07949 | 1/20 | 0.54 |
| ▸ | MET | P08581 | 1/20 | 0.54 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.54 |
| ▸ | PIM1 | P11309 | 1/20 | 0.54 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.54 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.54 |
| ▸ | FLT1 | P17948 | 1/20 | 0.54 |
| ▸ | LTK | P29376 | 1/20 | 0.54 |
| ▸ | GRK5 | P34947 | 1/20 | 0.54 |
| ▸ | KDR | P35968 | 1/20 | 0.54 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.54 |
| ▸ | FLT3 | P36888 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10257902 | 0.85 | CRBN (0.48) | ABL1CHEK1AURKADAPK3PRKD3 | |
| SCHEMBL19710787 | 0.84 | ABL1 (0.49) | ABL1CHEK1AURKADAPK3PRKD3 | |
| SCHEMBL16941450 | 0.83 | MB (0.38) | ABL1CHEK1AURKADAPK3PRKD3 | |
| SCHEMBL16941385 | 0.81 | CHEK1 (0.36) | ABL1CHEK1AURKADAPK3PRKD3 | |
| SCHEMBL16941381 | 0.80 | PIK3CG (0.37) | ABL1CHEK1AURKADAPK3PRKD3 | |
| SCHEMBL12396713 | 0.80 | CHEK1 (0.33) | ABL1CHEK1AURKADAPK3PRKD3 | |
| SCHEMBL16941452 | 0.79 | MB (0.35) | ABL1CHEK1AURKADAPK3PRKD3 | |
| SCHEMBL728499 | 0.77 | ABL1 (0.58) | ABL1CHEK1AURKADAPK3PRKD3 | |
| SCHEMBL16941391 | 0.76 | CYP11B1 (0.35) | ABL1CHEK1AURKADAPK3PRKD3 | |
| SCHEMBL14050975 | 0.75 | NNMT (0.37) | ABL1CHEK1AURKADAPK3PRKD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12030878-B2 | Substituted indole ether compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-07-09 | — | — | US | disclosed |
| US-20240067638-A1 | IMIDAZO[1,2-A]PYRIDINE AND [1,2,4]TRIAZOLO[1,5-A]PYRIDINE DERIVATIVES AS TLR9 INHIBITORS FOR THE TREATMENT OF FIBROSIS | BRISTOL MYERS SQUIBB CO (US) | 2024-02-29 | — | — | US | disclosed |
| US-11912703-B2 | 6-azaindole compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-02-27 | — | — | US | disclosed |
| US-11820768-B2 | 4-azaindole compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-11-21 | — | — | US | disclosed |
| US-20230322770-A1 | SUBSTITUTED HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF TLR9 | BRISTOL MYERS SQUIBB CO (US) | 2023-10-12 | — | — | US | disclosed |
| US-20230312565-A1 | 1H-PYRROLO[3,2-C]PYRIDINE AND 1H-PYRROLO[2,3-C]PYRIDINE DERIVATIVES AS TLR9 INHIBITORS FOR THE TREATMENT OF FIBROSIS | BRISTOL MYERS SQUIBB CO (US) | 2023-10-05 | — | — | US | disclosed |
| US-20230295122-A1 | 1H-BENZO[D]IMIDAZOLE DERIVATIVES AS TLR9 INHIBITORS FOR THE TREATMENT OF FIBROSIS | BRISTOL MYERS SQUIBB CO (US) | 2023-09-21 | — | — | US | disclosed |
| US-11739098-B2 | Substituted indole compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-08-29 | — | — | US | disclosed |
| US-20230139171-A1 | SYSTEM AND METHOD FOR INSTRUCTING ONE OR MORE WEATHER DRONES | SITA INFORMATION NETWORKING COMPUTING UK LIMITED (GB) | 2023-05-04 | — | — | US | disclosed |
| US-20210198252-A1 | SMYD INHIBITORS | EPIZYME INC (US) | 2021-07-01 | — | — | US | disclosed |
| US-8158624-B2 | Purine PI3K inhibitor compounds and methods of use | GENETECH, INC. (US) | 2012-04-17 | — | — | US | disclosed |
| US-20120035208-A1 | PYRAZOLOPYRIDINE PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH, INC. | 2012-02-09 | — | — | US | disclosed |
| US-20120010127-A1 | Compositions Comprising Multiple Bioactive Agents, and Methods of Using the Same | BERMAN JUDD M (CA) | 2012-01-12 | — | — | US | disclosed |
| US-20110301161-A1 | BENZIMIDAZOLE INHIBITORS OF LEUKOTRIENE PRODUCTION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-12-08 | — | — | US | disclosed |
| US-20110301161-A1 | BENZIMIDAZOLE INHIBITORS OF LEUKOTRIENE PRODUCTION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-12-08 | — | — | US | disclosed |
| US-20110172216-A1 | PYRAZOLOPYRIMIDINE PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2011-07-14 | — | — | US | disclosed |
| US-7879872-B2 | comprising (E)-N-methyl-N-(3-methylbenzofuran-2-ylmethyl)-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)acrylamide or pharmaceutically acceptable salts thereof; and gentamicin; wherein combination has an fractional inhibitory coconcentration index value of 0.3 against S. aureus 29213 | AFFINIUM PHARMACEUTICALS, INC. (CA) | 2011-02-01 | — | — | US | disclosed |
| EP-1633750-B1 | SYNTHESIS OF 5-SUBSTITUTED 7-AZAINDOLES AND 7-AZAINDOLINES | EISAI R&D MAN CO LTD (JP) | 2010-12-01 | — | — | EP | disclosed |
| US-20090318411-A1 | PURINE PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH, INC. | 2009-12-24 | — | — | US | disclosed |
| WO-2009003999-A2 | CHEMICAL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-01-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11820768-B2 | 4-azaindole compounds | TLR7, TLR9, TLR5 | ABL1 564/4885CHEK1 2955/4885AURKA 3214/4885 |
| US-20110301161-A1 | BENZIMIDAZOLE INHIBITORS OF LEUKOTRIENE PRODUCTION | LTC4S, LTB4R, LTB4R2 | ABL1 217/4885CHEK1 4264/4885AURKA 4116/4885 |
| US-20230295122-A1 | 1H-BENZO[D]IMIDAZOLE DERIVATIVES AS TLR9 INHIBITORS FOR THE TREATMENT OF FIBROSIS | TLR9, TLR1, TLR7 | ABL1 1590/4885CHEK1 2348/4885AURKA 4250/4885 |
| US-20090318411-A1 | PURINE PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | PIK3CA, PIK3CD, PIK3CG | ABL1 986/4885CHEK1 281/4885AURKA 1106/4885 |
| US-20120035208-A1 | PYRAZOLOPYRIDINE PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | PIK3CA, PIK3CD, PI4KA | ABL1 568/4885CHEK1 329/4885AURKA 760/4885 |
| US-11912703-B2 | 6-azaindole compounds | TLR7, TLR9, TLR5 | ABL1 541/4885CHEK1 2851/4885AURKA 3648/4885 |
| US-20120010127-A1 | Compositions Comprising Multiple Bioactive Agents, and Methods of Using the Same | DBI, SERPINB1, CTSF | ABL1 433/4885CHEK1 3908/4885AURKA 1410/4885 |
| US-20110172216-A1 | PYRAZOLOPYRIMIDINE PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | PIK3CA, PIK3CD, PI4KA | ABL1 700/4885CHEK1 214/4885AURKA 631/4885 |
| US-20210198252-A1 | SMYD INHIBITORS | SMYD3, SMYD2, SMURF2 | ABL1 2158/4885CHEK1 2720/4885AURKA 3154/4885 |
| US-20230322770-A1 | SUBSTITUTED HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF TLR9 | TLR9, TLR3, TLR1 | ABL1 116/4885CHEK1 1208/4885AURKA 4474/4885 |
| US-20230312565-A1 | 1H-PYRROLO[3,2-C]PYRIDINE AND 1H-PYRROLO[2,3-C]PYRIDINE DERIVATIVES AS TLR9 INHIBITORS FOR THE TREATMENT OF FIBROSIS | TLR9, TLR1, TLR7 | ABL1 2171/4885CHEK1 2813/4885AURKA 4446/4885 |
| US-20240067638-A1 | IMIDAZO[1,2-A]PYRIDINE AND [1,2,4]TRIAZOLO[1,5-A]PYRIDINE DERIVATIVES AS TLR9 INHIBITORS FOR THE TREATMENT OF FIBROSIS | TLR9, TLR1, TLR7 | ABL1 847/4885CHEK1 2639/4885AURKA 3128/4885 |
| US-12030878-B2 | Substituted indole ether compounds | TLR7, TLR8, TLR1 | ABL1 472/4885CHEK1 2912/4885AURKA 3579/4885 |
| US-11739098-B2 | Substituted indole compounds | TLR7, TLR1, HTR7 | ABL1 733/4885CHEK1 2844/4885AURKA 4806/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.